Was searching FDA novel drug approvals for 2023 https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 and noticed the below timeframe from Priority Review to approval was just under 6 months for Orserdu https://www.drugs.com/newdrugs.html
Based on this maybe end of February for FDA notification (approval or otherwise) at best guess?
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-38
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.39 |
Change
-0.470(2.37%) |
Mkt cap ! $2.478B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $10.38M | 534.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2680 | $19.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.41 | 362 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |